Myocarditis in Athletes Is a Challenge: Diagnosis, Risk Stratification, and Uncertainties by Eichhorn, Christian et al.
HAL Id: hal-02473901
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02473901
Submitted on 17 Feb 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Myocarditis in Athletes Is a Challenge: Diagnosis, Risk
Stratification, and Uncertainties
Christian Eichhorn, Loïc Bière, Frédéric Schnell, Christian Schmied, Matthias
Wilhelm, Raymond Kwong, Christoph Gräni
To cite this version:
Christian Eichhorn, Loïc Bière, Frédéric Schnell, Christian Schmied, Matthias Wilhelm, et al.. My-
ocarditis in Athletes Is a Challenge: Diagnosis, Risk Stratification, and Uncertainties. JACC: Car-
diovascular Imaging, Elsevier/American College of Cardiology, 2020, 13 (Issue 2 Part 1), pp.494-507.
￿10.1016/j.jcmg.2019.01.039￿. ￿hal-02473901￿
1 
 
Myocarditis in athletes is a challenge – diagnosis, risk stratification and uncertainties 
 
Christian Eichhorn, BSc1, Loïc Bière, MD, PhD 1,2, Frédéric Schnell, MD, PhD3, Christian 
Schmied, MD4, Matthias Wilhelm, MD5,, Raymond Y. Kwong, MD, MPH1, Christoph Gräni, 
MD, PhD1,5,6 
 
1 Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of 
Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, USA 
2 Institut MitoVasc, Laboratoire Cardioprotection, Remodelage et Thrombose, University of 
Angers, Angers, France; Department of Cardiology, University Hospital of Angers, Angers, 
France 
3 Rennes University Health Centre, Sports Medicine Division; Physiology Laboratories, Rennes-
1 University, Rennes, France 
4 Department of Cardiology, University Heart Center, Zurich, Switzerland. 
5 Department of Cardiology, Swiss Cardiovascular Center, University Hospital Berne, Berne, 
Switzerland 
6 Cardiac Imaging, Department of Nuclear Medicine, University Hospital Zurich, Zurich, 
Switzerland 
 
Corresponding Author:  
Christoph Gräni, MD, PhD 
Department of Cardiology, Cardiac Imaging 
Swiss Cardiovascular Center 
University Hospital Berne 
Freiburgstrasse  
CH - 3010 Berne, Switzerland 
Tel: +41 31 632 45 08 
Email: christoph.graeni@insel.ch 
 
Brief title: CMR Myocarditis in athletes 
Word count:  7459  
 
Disclosures: None 
  
Ac
ce
pte
d m
an
us
cri
pt
2 
 
Abstract 
Presentation of myocarditis in athletes is heterogeneous and establishing the diagnosis is 
challenging with no current uniform clinical gold-standard. The combined information from 
symptoms, electrocardiography, laboratory testing, echocardiography, cardiac magnetic 
resonance imaging (CMR), and in certain cases endomyocardial biopsy (EMB) helps to establish 
the diagnosis. Most patients with myocarditis recover spontaneously; however, athletes may be 
at higher risk of adverse cardiac events. Based on scarce evidence and mainly autopsy studies 
and expert’s opinions, current recommendations generally advise abstinence from competitive 
sports ranging from 3 to 6 months. However, the dilemma poses that (un-) necessary prolonged 
disqualification of athletes in order to avoid adverse cardiac events, can cause considerable 
disruption to training schedules and tournament preparation, and leading to a decline in 
performance and ability to compete. Therefore, better risk stratification tools are needed. Using 
latest available data, this review contrasts existing recommendations and presents a new 
proposed diagnostic flowchart putting a greater focus on the use of CMR imaging in athletes 
with suspected myocarditis. This may enable cardiac caregivers to risk stratify athletes with 
suspected myocarditis more systematically, and furthermore allow for pooling of more unified 
data. To modify recommendations regarding sports behavior in athletes with myocarditis, more 
evidence, based on large multicenter registries including CMR and EMB, is needed. In the 
future, physicians might rely on combined novel risk stratification methods, by implementing 
both noninvasive- and invasive tissue characterization methods. 
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Abbreviations: 
BNP = Brain Natriuretic Peptide 
CAD = Coronary Artery Disease  
CMR = Cardiac Magnetic Resonance Imaging 
ECG = Electrocardiography 
ECV = Extracellular Volume Fraction  
EMB = Endomyocardial Biopsy 
LGE = Late Gadolinium Enhancement 
LLC = Lake Louise Criteria 
LVEF = Left Ventricular Ejection Fraction 
MACE = Major Adverse Cardiovascular Events 
RV = Right Ventricular 
RVEF = Right Ventricular Ejection Fraction 
SCD = Sudden Cardiac Death 
TTE = Transthoracic Echocardiography 
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Introduction 
Myocarditis is an underlying cause of sudden cardiac death (SCD) in young athletes (1-
3). While the beneficial effects of exercise on both cardiovascular and general health are 
irrefutable, some evidence has emerged showing that excessive levels of exercise in the presence 
of an infection and particularly in myocarditis can be harmful (2,4). Current recommendations 
state that after a case of myocarditis abstinence from competitive sports lasting between 3 to 6 
months is generally recommended; this, however, can be extended to up to 1 year and is based 
on scarce evidence, mainly autopsy studies and experts’ opinions (5-7). However, prolonged 
disqualification of athletes is disruptive to athletic conditioning, which may lead to performance 
drop and inability to compete. In order to avoid adverse cardiac events and better risk stratify 
athletes with myocarditis, prognostic information may be gained from the application of using 
cardiac magnetic resonance imaging (CMR) (8). This review presents a new proposed diagnostic 
flowchart (Central Illustration) based on recent evidence and existing recommendations, which 
integrates the use of CMR imaging for diagnosing and risk stratification of athletes with 
suspected myocarditis.  
Myocarditis in Athletes 
In post-mortem studies of athletes who died from SCD, myocarditis was diagnosed in up 
to 8% (9,10). This represents the third most common cause after autopsy-negative sudden 
unexplained death and coronary artery anomalies (1). It is uncertain if physical activity is truly 
necessary to trigger malignant arrhythmias as the majority of SCD, especially due to 
myocarditis, did not occur during or immediately after exercise but at rest (1,11). 
Viral infections, namely with enterovirus, Coxsackie B, Parvovirus B19 and Human Herpes 
Virus 6 are the most common responsible infectious pathogens in myocarditis (12,13). Initially, 
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these pathogens directly affect the myocardium, followed by autoimmune myocardial injury, 
which ultimately results in myocardial remodeling potentially leading to dilated cardiomyopathy. 
Another factor that determines the underlying causative pathogen may be governed by the type 
of sports performed. For example, cross-country runners have greater exposure to tick-bite-
transmitted infections (Borrelia Burgdorferi). Myocarditis can also be caused by a great variety 
of medical drugs as well vasculitic or toxic causes (14), underlining the attention of considering 
co-morbidities in athletes. In general, non-infectious causes of myocarditis are rare in athletes 
but can include illicit drugs (15), illustrating the importance of lifestyle history in athletes.  
Pathogenesis and Contributing Effect of Strenuous Exercise 
The general hypothesis is that moderate exercise, which does not comprise of a common 
definition amongst studies of runners, is protective. However, more intense endurance training, 
typically that for a marathon may increase the likelihood of a systemic inflammatory response 
and susceptibility to viral upper respiratory tract infections (16). As a result, acute myocarditis 
can ensue and lead to an interaction between an environmental trigger and the host’s immune 
system, leading to three phases of disease progression: acute viral, subacute immune and chronic 
phase, with 12 - 25% developing dilated cardiomyopathy (17). While the viral phase is often 
short-lived and not clinically detected, pathogens may reach the myocardium and affect it 
through direct myocyte injury as well as through activation of the innate immune system; this 
results in subacute and chronic inflammation, which leads to myocyte necrosis, fibrosis and 
ultimately adverse cardiac remodeling (17), pre-disposing an individual to arrhythmias. Exercise, 
particularly under extreme physical exertion, is associated with a higher propensity to 
arrhythmogenicity (18), which murine studies have shown to be due to an intensified 
inflammatory response in subjects exposed to extreme physical exertion (18,19). Even after the 
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myocardium has recovered after an episode of myocarditis, the chronic myocardial inflammatory 
process secondary to pathogenic autoimmunity may persist, where cytokines carry on to exert 
pro-arrhythmic effects and trigger circuit activity (20). Therefore, athletes with a history of 
myocarditis, or in certain cases even just a minor infection, may pose an increased risk for 
adverse cardiac events if physical exercise is continued. 
Clinical Presentations and the Use of Biomarkers, Viral Serology, Electrocardiogram and 
Transthoracic Echocardiography 
Myocarditis presents a challenging clinical scenario given its heterogeneous presentation. 
The suspicion of myocarditis may be raised when athletes complain of chest pain or indeed any 
other cardiac symptom in the context of general malaise with abnormal biomarkers, ECG or 
transthoracic echocardiogram (TTE) changes. This particularly affects those individuals who 
present with new onset left ventricular (LV) dysfunction after viral infection or prodromal 
symptoms in recent weeks. One must be aware that signs of myocarditis may resemble those of 
physiological changes in the athlete’s heart (Table 1). 
Biomarker and Viral Serology  
Other than an increase in troponin, there are no other specific biomarkers indicative of 
myocardial injury due to myocarditis. Evidence for viral serology has not proved sufficient as 
shown by a prospective study by Mahfoud et al., which determined the sensitivity and specificity 
of virus serology to be 9% and 77% respectively. Only 5 out of 124 patients were shown to have 
viral serology consistent with the virus that was detected upon EMB (21). Where there is clinical 
suspicion or high risk, testing for hepatitis C, human immunodeficiency virus, Lyme disease or 
rickettsia is warranted.  A recent study characterizing the causes of raised troponin in those 50 
years or less including 6081 patients showed that myocarditis was the second most common 
A
c
p e
d m
nu
cri
pt
6 
 
cause of raised troponins after myocardial infarction (22), further underlining the importance of 
myocarditis as a diagnosis especially in young and middle-aged patients. A meta-analysis 
including thirty-three studies with a total of 1045 athletes, mainly participating in endurance 
sports ranging from short runs to ultra-marathons showed that cardiac troponin was elevated 
above the 99th percentile in up to 83% of individuals following prolonged exercise (23). 
However, the troponin release tends to be less prominent and monophasic rather than biphasic 
and resolves faster than in myocardial injury as caused by myocarditis or acute coronary 
syndrome. Therefore, in the absence of an acute coronary syndrome, a judgement on the nature 
of the myocardial insult should consider the prominence of the rise in troponin, the timeframe of 
a high troponin level and the time elapsed since endurance exercise. Nevertheless, a recent study 
by Berg et al. has concluded that absolute baseline levels of cardiac enzymes and inflammatory 
biomarkers do not sufficiently represent the level of Late-Gadolinium Enhancement (LGE) by 
CMR in myocarditis. Further, it does not predict change in LGE at 3 months follow-up and does 
not correlate with improved LGE when a decrease in cardiac enzymes and inflammatory 
biomarkers is observed (24). Based on their findings, they concluded that it was not sufficient to 
simply use clinical findings, cardiac enzymes and inflammatory markers to monitor myocarditis 
and that CMR adds important additional information to current diagnostic techniques.  
Electrocardiogram 
Patients with myocarditis may present with unspecific ST-elevations, PQ-depression, 
QTc prolongation or T-wave inversion, which, in some cases, might be difficult to distinguish 
from normal variants in healthy athletes (Table 1) (25,26). In our recent report looking at the 
prognostic value of CMR tissue characterization in risk stratifying patients with suspected 
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myocarditis, only 42% of the 670 suspected myocarditis patients showed abnormal ECGs, with 
no significant difference between those where LGE was present and absent (8).  
Transthoracic Echocardiography 
Generally, the heart of trained athletes can present with various structural changes 
depending on the dynamic component of the type of exercise performed (27) – endurance 
training, such as that for a marathon, increases isotonic load on working muscles that can lead to 
increased LV dimensions, while high isometric load on working muscles, such as in weight 
lifting, can result in increased LV wall thickness. To what degree different types of exercise 
involve dynamic and static components has been further described by Mitchell et al. (28) and 
may help physicians to counsel athletes with cardiovascular abnormalities in regards to particular 
types of competitive exercise. Compared to healthy athletes, in a case of myocarditis, there are 
no specific features in TTE. Myocarditis can resemble dilated, hypertrophic, or restrictive 
cardiomyopathy with local wall motion abnormalities and/or pericardial effusion (29). 
Nonetheless, TTE can be of prognostic value in fulminant myocarditis, which presents with 
normal chamber size and severe impaired systolic left ventricular ejection fraction (LVEF) (30). 
It has been shown that regional wall motion abnormalities following myocarditis in athletes can 
be exacerbated by exercise in contrast to normal-/depressed LVEF among healthy athletes, 
which normalizes during exercise (31). TTE is therefore an important and feasible tool to fully 
assess LV function and wall motions at presentation and at follow-up. The LV remodeling index 
was identified to differentiate athletes from patients presenting with dilated and hypertrophic 
cardiomyopathy (32). However, TTE cannot always help to differentiate athlete’s heart from 
other pathological structural or functional changes and in those cases CMR may be indicated as 
it also helps to identify further diagnostic information beyond geometric measures (33). 
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Invasive Coronary Angiography and Endomyocardial Biopsy 
Generally, coronary artery disease (CAD) should be ruled out first using invasive or 
noninvasive imaging or a clinically low-pretest probability for CAD in individuals presenting 
with suspected myocarditis. If at the time of CMR scanning, no signs of active inflammation on 
T2-weighted imaging or T2 mapping is present, clinicians could consider performing CMR 
stress-perfusion to rule out ischemia. In this setting, CMR may further help to differentiate 
between an ischemic event with its typical pattern of endocardial LGE presence in coronary 
vessel distribution territory versus epicardial LGE in myocarditis (e.g. in athletes with low pre-
test probability and no indication for invasive coronary angiography).  Concerning the use of 
endomyocardial biopsy (EMB), European and American recommendations differ slightly (Table 
2). EMB is an invasive diagnostic test with high specificity and complication rates as low as 
<1% in experienced centers (34,35). EMB can differentiate between different types of 
inflammation (infectious, autoimmune, idiopathic) causative of myocarditis and may therefore 
guide treatment and prognosis. This is particularly recommended in life-threatening 
presentations or unexplained reduced systolic LV function (14). However, it lacks sensitivity and 
exhibits high false negative results (sampling error). To avoid focal sampling error, EMB is 
preferably performed soon after presentation and multiple samples of sufficient size (1 – 2 mm) 
should be taken from both ventricles (35,36). Additionally, diagnosis by EMB can be improved 
by analyzing the viral genome through DNA-RNA extraction and RT-PCR amplification (37). 
This has the advantage of knowing exactly which pathogen is causing disease as different viruses 
have different effects on myocardial and vascular tissue and affect different areas of the 
myocardium, which in turn may affect presenting signs and symptoms as well as ECG. 
Historically, it has not been clear whether CMR helps in guiding biopsy and improving 
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sensitivity/specificity of EMB (35,38). A study by Baccouche et al. suggests a diagnostic 
synergy in using both CMR and EMB as complementary diagnostic tools in troponin-positive 
patients without CAD, identifying 78/82 myocarditis patients (95%) when applied together, 
which was superior to both CMR and EMB when applied individually (39). Recent evidence of 
real-time CMR-guided EMB in a porcine pre-clinical in-vivo model suggest that CMR-guidance 
of EMB may significantly improve sensitivity and specificity of EMB (40). However, whether 
EMB would help to earlier risk stratify athletes with regard to sports abstinence counseling is 
unknown. Therefore, performing EMB generally has the greatest potential benefit in cases where 
CMR cannot confirm a diagnosis of myocarditis or in cases with unclear depressed LVEF 
(Central Illustration). 
Cardiac Magnetic Resonance Imaging 
CMR plays a major role in evaluating the etiology of chest pain syndromes and suspected 
myocarditis but recommendations about the exact role of CMR in diagnosis and follow-up of 
myocarditis (Table 2) (41) are outdated due to new data and improvements in imaging technique. 
CMR has evolved as the primary noninvasive diagnostic modality in suspected myocarditis 
cases, with particularly high sensitivity (81%), specificity (71%)  and diagnostic accuracy (79%)  
in acute myocarditis (42), given several technical advantages. Beyond the assessment of wall 
motion and LVEF, CMR is a noninvasive modality that allows tissue characterization with 
visualization of myocardial edema and fibrosis (43).  
The Lake Louise Criteria (LLC) (44) utilized in the diagnosis of suspected myocarditis 
combine different CMR techniques to detect intramyocardial edema by T2-weighted imaging, 
fibrosis by  LGE, typically in a non-ischaemic distribution, as well as hyperemia by myocardial 
early gadolinium enhancement (EGE). A certain number of patients with biopsy proven 
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myocarditis have no LGE and do not fulfil the LLC (35,45); reasons for this may include that 
active myocarditis may not always lead to regions of necrotic myocytes that are large enough to 
be detected by CMR. Moreover, the optimal time point after onset of symptoms for a CMR scan 
has not yet been determined yet and (too) early CMR scanning may yield false negative findings 
which necessitate repeat scanning (Central Illustration).  
CMR may detect isolated myocarditis-like LGE on CMR in an athlete with non-acute 
symptoms (e.g. syncope, or palpitations without any clinical signs of acute myocarditis). 
Whether these findings represent an acute myocarditis, a myocarditis in a late stage without 
presence of myocardial edema, a resolved myocarditis or another pathology can be challenging 
(see Figure 2), however, CMR can be considered the most suitable noninvasive modality for 
differentiation of different underlying cardiac causes.  
T2 weighted imaging, T1 - and T2 mapping techniques 
LLC are now often complemented by novel CMR techniques such as native T1 and T2 
mapping as well as extracellular volume fraction (ECV) measurement to provide a higher 
sensitivity and specificity (46,47). Native T1 mapping values are affected by both edema and 
extracellular expansion and is therefore able to detect myocarditis at various stages, whereas T2 
mapping evaluates free water content that is normally present in the acute phase of myocarditis 
and then gradually normalizes over months - this is relevant for cardiac caregivers evaluating the 
course of myocarditis as it is the only technique that can adequately discriminate between 
myocarditis and noninflammatory cardiomyopathies in patients with symptoms lasting longer 
than 2 weeks (48,49). A recent meta-analysis by Pan et al. (48) comparing the diagnostic 
performance of ECV, native T1 mapping and T2 mapping versus LLC for detection of acute 
myocarditis including 17 studies and 1308 subjects, has shown that only native T1 mapping had 
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significantly better sensitivity than LLC, while other parameters had comparable diagnostic 
performance to LLC and provided distinct advantages for evaluating myocarditis. The meta-
analysis shows that LLC have been firmly established in clinical practice and that the use of 
native of T1 mapping can further enhance CMR accuracy in diagnosing myocarditis. These 
findings are supported by another meta-analysis including 22 studies by Kotanidis et al. (50), 
which similarly concludes that native T1 mapping has a significantly higher diagnostic accuracy 
compared to all other index tests: native T1 mapping showed an area under the curve (AUC) of 
0.95 compared to T2 mapping with an AUC of 0.88 and LLC of 0.81 and will therefore likely be 
implemented in the upcoming updated Lake Louise Criteria. Additionally, the authors showed 
that T2 mapping was superior to T2-weighted and EGE imaging, suggesting that both EGE and 
T2-weighted imaging could be replaced by T1 - and T2 mapping respectively (50). The role of 
ECV is less clear at this stage. In our subset analysis, ECV showed a significant association with 
major adverse cardiovascular events (MACE) and death and may therefore be of additional 
benefit in a routine CMR for risk stratification in suspected myocarditis (8).  
However, due to its novelty, it is important that further studies on the inherent characteristics of 
T1 mapping will be performed. As T1- and T2 mapping values are vendor and site specific, 
standardization of these mapping techniques and understanding how confounding factors will 
influence them in real-life clinical practice outside of the research setting is needed (51). 
Furthermore, native T1 prolongation becomes less specific to myocarditis over time as early 
inflammation is replaced by fibrotic tissue, which, in patients with chronic symptoms, can be due 
multiple cardiac pathologies. To truly implement changes to diagnostic criteria, head-to-head 
comparisons performed at multiple centres would be desirable (52).  
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In our own sub-group analysis, T2 weighted imaging has demonstrated a significant 
association with MACE (8). Other studies were not able to show this predictive value, possibly 
due to the low patient number and the fact that T2 weighted imaging is prone to artefacts. Our 
study is supported by the study of Spieker et al. who could show that myocardial edema detected 
with T2 mapping has prognostic value in patients with myocarditis. Furthermore, it seems that 
T2 mapping is more robust and less prone to artefact compared to T2 weighted imaging and may 
be the better sequence for edema assessment in patients with suspected myocarditis (53,54).  
Late Gadolinium Enhancement 
Whether any LGE presence in athletes may be the substrate for ventricular tachycardia 
(e.g. from previous myocarditis or other causes) is unknown (55,56). Studies have reported a 
high rate of coincidentally detected LGE in athletes (55-57). In two recent series, which included 
athletes who had undergone CMR because of abnormal screening (ECG changes or ventricular 
arrhythmias) first line examination but structurally normal hearts on echocardiographic imaging, 
a high rate of cardiac events during follow-up was reported in those with large areas of sub-
epicardial LGE (58,59). Although these athletes had no definite history of myocarditis, the 
authors hypothesise that due to the typical non-ischemic epicardial pattern of LGE a silent 
myocarditis is most probably the underlying cause.  Although rather untypical, other causes like 
arrhythmogenic right ventricular cardiomyopathy (ARVC) with mainly left heart involvement 
are not completely excluded, however, it is generally more likely that myocarditis mimics an 
ARVC than vice versa (60). Furthermore, in the acute stage differential diagnosis of myocarditis 
and ARVC does not change the sports recommendation, but does change diagnostic downstream 
testing. The mentioned studies highlight the fact that subepicardial fibrosis may otherwise not 
have been detected by echocardiography alone and that CMR plays an important role especially 
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in athletes with ventricular arrhythmias. These findings support the argument to use CMR early 
for risk stratifying athletes with suspected myocarditis, which, when LGE is present, most 
commonly presents with subepicardial LGE (8,61). Our group had recently shown that in 670 
patients with suspected myocarditis with a median follow-up of 4.7 years, CMR is not only a 
powerful diagnostic but also a prognostic tool (8). In fact, patients with suspected myocarditis 
and presence of LGE (n = 296, 44%) showed a doubled risk for MACE at follow-up. Regarding 
location and pattern, septal and mid-wall LGE demonstrated strongest significant associations 
with MACE (Hazard Ratio of 2.6 and 2.4). A patchy distribution portended to a near 3-fold 
increased hazards to MACE and LGE extent (increase by 10%) corresponded to a near eighty 
percent increase in risk of MACE. The Italian Multicenter study on Acute Myocarditis 
(ITAMY), which included 374 patients with acute myocarditis and preserved LVEF, similarly 
concluded that in these patients LGE in the mid-wall layer of the anteroseptal myocardial 
segment is associated with a worse prognosis (61). Mahrholdt et al. found that varying patterns 
of LGE are associated with different viruses; parvovirus B19 was associated with inferolateral 
LGE, while anteroseptal LGE was associated with either human herpesvirus 6 or the combined 
presence of the two viruses (62). On the contrary, a normal CMR study corresponded to low 
annual MACE and death rates of 0.8% and 0.3% respectively in our study (8), and no events 
were recorded in the ITAMY study (61). Alluding to the diagnostic usefulness and common 
application of CMR, our study showed that only 57 (9%) of patients underwent EMB with 
mostly unspecific results, which is consistent with other studies (44,63,64),  while the ITAMY 
study (61) solely relied on LLC for diagnosis of acute myocarditis in 95% of cases. The 
prognostic power of LGE presence on CMR in suspected myocarditis is similarly shown by both 
our study (8) and the ITAMY study (61). It is to note that our study shows lower event rates as 
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we did not select patients who have already been diagnosed with acute myocarditis according to 
LLC; rather we chose a more real-life clinical setting, where low-risk patients are more likely to 
be included in the patient population; additionally, ITAMY and our study showed slight 
differences in MACE criteria.  
Another important risk factor that will require further studies evaluating its prognostic 
strength is LV remodeling. Recently, Filippetti et al. (65) showed that not only the lack of LGE 
but also of any adverse LV remodeling at mid-term control scanning resulted in better outcomes 
in acute myocarditis.  
CMR used as a diagnostic and risk stratification tool can help to identity how physicians 
should approach treatment of an athlete with current or recent infection and suspected 
myocarditis, what to recommend regarding disqualification from exercise and may help to fill 
apparent evidence gaps (Central Illustration). Assuming that cardiac centres have sufficient CMR 
experience and image quality is adequate, CMR can act as a gatekeeper in the diagnosis of 
myocarditis and a revised diagnostic algorithm that incorporates CMR in a uniform fashion will 
help to create necessary outcome data. While athletes with LGE presence may need to undergo 
CMR follow-up, absence of LGE on CMR scanning in athletes with suspected myocarditis could 
be interpreted as ‘low-risk’ and they might get allowed to go back to exercise after clinically 
resolved inflammation (66). 
Therapy 
In most cases, myocarditis is a benign pathology and resolves favorably. Currently, no 
randomized controlled trials for optimal therapy exist. Current recommendations (14)  endorse 
heart failure medication as supportive therapy for LV dysfunction in myocarditis. Beta-blockade 
improves LVEF and reduces hospitalization while increasing survival; carvedilol has been 
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shown to exert cardioprotective effects (67), while metoprolol may play a role in increased 
inflammation (68). Non-steroidal anti-inflammatory agents are generally only advisable in 
patients with peri-/myocarditis with normal LVEF and chest pain (69). The use of 
immunosuppression with a combination of cortisol and azathioprine for 6 months has shown 
benefits in a single-centre study when there is no viral persistence (70). However, current 
recommendations do not include these immunomodulatory therapies. Of note, 
immunosuppression may be useful and improve outcome in patients with a particular form of 
myocarditis, a giant cell myocarditis (71). Beside heart failure therapy, supportive arrhythmia 
management is recommended. Specific recommendations for arrhythmias as well as  intracardiac 
defibrillator implantation in myocarditis do not exist and hence, management should be in 
concordance with current arrhythmia guidelines. Wearable life-vests (72) may play a future role 
in athletes, who may want to try getting back into some low intensity exercise at an earlier stage, 
even at an increased risk of SCD since the effect of adverse remodeling will not be mitigated (if 
the physical aspects of the type of sports allow it, e.g. spinning). 
Follow-up and sports restriction 
First and foremost, athletes with acute myocarditis need to refrain from physical exercise, 
especially from competitive sports. Based on the most recent scientific statement from the 
AHA/ACC, it is recommended that athletes with probable or definite diagnosis of myocarditis 
should not participate in competitive sports while active inflammation is present (Class III, Level 
of evidence C) (Table 3), signs of which are most easily detected using CMR (e.g. T2-weighted 
imaging for edema). This recommendation applies across patient age groups, genders and left 
ventricular functions. Before returning to competitive sports, athletes should undergo an 
echocardiography, Holter monitoring – preferentially before and during a work-out, and an 
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exercise ECG no less than 3 - 6 months after initial illness (Class I, Level of Evidence C). There 
is currently no evidence available on the ‘safe’ level of exercise in the 3 - 6 months “competitive 
sports abstinence” period in athletes with myocarditis. High intensity training would be rather 
categorized as competitive sports and should not be recommended (see case presentation in 
Figure 1) during this period. Yet, the role of moderate or isometric exercise is still unclear. It is 
an individual case by case decision and according to the “Exercise in heart failure” consensus 
document (73) moderate exercise at 50% VO2peak or 60% from their maximum predicted heart 
rate is recommended and may also be translated to myocarditis patients. However, clinical and 
laboratory absence of inflammation and absence of arrhythmias are a requirement to return to 
any exercise levels. Other missing gaps include whether different levels of ‘severity’ of 
myocarditis or locations, patterns and size of LGE require different lengths of sports abstinence 
and whether serial CMR scans are needed to guide therapy and recommendation regarding sports 
behavior. Furthermore, to what extent genetic predisposition determines disease progression and 
how clinical examination, biomarkers, ECG and EMB can help to anticipate adverse outcomes is 
still unclear.  
CMR has the added advantage to unveil possible acute myocarditis by identifying 
myocardial edema even in absence of LGE. In order to avoid adverse cardiac events, this may 
allow  clinicians to make conservative recommendations regarding returning to exercise until 
inflammation is resolved of the myocardium in the follow-up CMR (see Central Illustration).    
In a small study evaluating 28 myocarditis patients (non-athletes), patients with decreasing LGE 
at follow-up had a lower event rate compared to those with greater amount of LGE (74). 
However, at present it remains unresolved if resolution of myocarditis-related LGE should be a 
requirement prior to returning to competitive sports (5). 
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Recommendations should be applied not only to competitive athletes but also to those 
participating in recreational sports. Two studies showed that most myocarditis related SCD most 
frequently occurs in recreational athletes (75,76). Current European recommendations reflect this 
in that they generally recommend no competitive sports for those diagnosed with myocarditis 
(6), while also extending this to recreational and amateur sports activities (7,14);  clinical 
assessment in the absence of abnormal LVEF and arrhythmias is necessary prior to resuming 
competitive sports. CMR features such as T2-weighted imaging, LGE and T1/T2 mapping with 
regard to sports behavior recommendations are currently not included. Further research will be 
needed in order to assess how this novel mapping techniques can help treating physicians to 
counsel athletes with myocarditis.  
Conclusion 
 Information leading to sports restriction recommendations in athletes with 
myocarditis are mainly based on autopsy studies, animal models and experts’ opinions. Recent 
evidence showed that CMR as a non-invasive imaging tool plays an important role in the risk 
stratification of patients with suspected myocarditis. To modify recommendations regarding 
sport behavior in physically active individuals with myocarditis, more evidence, based on large 
multicenter registries including CMR and immunochemistry EMB, is needed. Physicians might 
rely in the future on combined novel risk stratification methods, which will be likely improved 
by implementing both noninvasive- and invasive tissue characterization methods using CMR and 
EMB. 
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Tables 
Table 1. Challenges in ECG, biomarkers and noninvasive imaging characteristics in 
patients with athlete’s heart versus acute myocarditis  
 
  
Differentiating Features 
Athletes Heart 
 
Differentiating Features 
Myocarditis 
Symptoms Asymptomatic Symptomatic 
ECG/Holter 1. Specific ECG changes 
such as early 
repolarization/ST 
segment elevation, T-
wave inversion in V1-
V3 ≤age 16 years old, 
ST elevation followed 
by T wave inversion 
V1-V4 in black athletes 
1. Unspecific ECG 
changes. Possible 
PQ depression, ST 
elevation in multiple 
leads.   
Biomarkers/ 
Inflammatory markers 
1. Troponin elevation 
mild and normalizes 
quickly. May be 
present in ultra-
endurance athletes. 
1. Troponin elevation 
mild to high   
2. Others: BNP 
elevation, Creatine-
Kinase, 
Leucocytosis, 
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2. Others: BNP mildly 
elevated after ultra-
endurance exercise 
elevated C-reactive 
Protein, elevated 
Erythrocyte 
sedimentation rate 
TTE 1. Ejection fraction: 
Sub-depressed LVEF 
and/or RVEF in ultra-
endurance athletes, 
normalizes when 
exercising. 
2. Dilatation and 
eccentric remodeling, 
no focal regional wall 
motion abnormalities 
 
1. Ejection fraction: 
Depressed LVEF, 
can further decline 
when exercising. 
2. Focal hypokinesia 
at rest or during 
exercise (regional 
wall motion 
abnormalities) 
3. Pericardial 
Effusion 
CMR 1. LGE typically absent; 
possible LGE if 
previous silent 
myocarditis 
2. Edema rarely present 
after exercise 
1. LGE: normal or 
specific mid to sub-
epicardial LGE 
pattern 
2. Edema present 
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Table 2: Recommendations regarding endomyocardial biopsy and the use of CMR in 
patients with suspected myocarditis 
 
Endomyocardial biopsy recommendations 
ESC/ACC/AHA 2007 
Scientific Statement (77,78) 
ESC 2013 Position 
Statement (14) 
ACC/AHA 2013 HF 
Management Guidelines (79) 
Presents 13 scenarios in 
which EMB might be 
considered. Class IB 
recommendations for ‘EMB 
in the setting of unexplained, 
new-onset heart failure of… 
… <2 weeks’ duration 
associated with a normal-
sized or dilated left ventricle 
in addition to hemodynamic  
compromise.’   
 
And 
  
… 2 weeks’ to 3 months’ 
duration associated with a 
dilated left ventricle and new 
Use EMB widely in order to 
make a diagnosis, 
management plan and 
prognosis according to 
whether viral genomes and 
inflammation are present.  
Routine EMB in all cases of 
heart failure is not 
recommended. In those 
patients progressing rapidly 
or suffer from unexplained 
cardiomyopathy and where 
active myocarditis, in 
particular giant cell 
myocarditis is suspected, 
should undergo EMB. 
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ventricular arrhythmias, 
Mobitz type II second- or 
third-degree atrioventricular 
(AV) heart block, or failure 
to respond to usual care 
within 1 to 2 weeks.’ 
Differences: 
European and US guidelines differ in so far as European guidelines do recommend routine 
EMB in myocarditis cases, whereas US guidelines are more conservative in using EMB. 
Recommendations regarding the use of CMR in patients with suspected myocarditis 
JACC 2009 White Paper 
(44) 
ESC 2013 Position 
Statement (14) 
ACC/AHA 2015 Scientific 
Statement (80) 
Recommends the use of 
CMR as part of a more 
comprehensive diagnostic 
approach. Particularly in 
patients with significant 
ongoing, recurring or 
persisting inflammation, it is 
able to determine the extent 
and regional distribution of 
reversible and irreversible 
Reasonable to perform CMR 
prior to EMB but only if the 
situation is not life-
threatening. CMR should not 
replace EMB as a diagnostic 
tool. The use of the ‘Lake – 
Louise – Criteria’ is 
recommended.  
Pericardial effusion on CMR 
or characteristic alterations in 
tissue signal on T2- or T1-
weighted images and the 
presence of LGE are 
sufficient for the diagnosis of 
probable acute myocarditis if 
a clinical syndrome that 
includes acute heart failure, 
angina-type chest pain, or 
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myocardial injury, as well as 
to detect functional 
abnormalities. Proposes 
‘Lake – Louise – Criteria’.  
Pooled diagnostic accuracy 
of 78% with a sensitivity of 
67% and specificity of 91% 
for diagnosis of myocarditis 
on CMR compared to biopsy 
as the gold-standard.  
myopericarditis of <3 
months’ duration is present. 
Differences: 
US recommendations are more inclusive of CMR as a diagnostic tool and do not require 
EMB in the assessment of myocarditis, whereas European recommendations include the use 
CMR only complimentary to EMB.  
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Table 3: Sports Restriction Recommendations in athletes with myocarditis 
ESC 2005 Consensus Document 
(6) 
ESC 2006 Position 
Paper (7) 
ACC/AHA 2015 Scientific 
Statement (80) 
Medical history, physical 
examination, 12-lead ECG and 
echocardiography. 
No competitive exercise during 
active myocarditis or 
pericarditis. First control within 
6 months through assessment by 
the above modalities as well as 
exercise testing; if no symptoms, 
normal LV function and no 
arrhythmias allowed to continue 
with all competitive sports. 
Follow-up according to 
individual case.  
Medical history, 
physical examination, 
12-lead ECG and 
echocardiography 
according to individual 
case assessment. 
Temporary exclusion of 
both competitive and 
recreational athletes 
independent of age, 
gender and severity for a 
minimum of 6 months. 
Clinical assessment 
prior to resumption 
required. 
 
Biopsy not required to guide 
clinical management but 
recommended in certain cases 
(see Table 2). Time period of 
absence from exercise will 
depend on severity of initial 
symptoms. Based on 
experimental models, a resting 
period of at least 3 – 6 months 
is recommended. No exercise 
during active inflammation for 
patients with probable or 
definite myocarditis. Within 3 
– 6 months of presentation, 
ECG, 24-hr Holter and exercise 
ECG to assess fitness to 
exercise – normal systolic 
function, normal biomarkers 
and absence of arrhythmias 
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recommended before exercise 
resumption.  
Unclear whether myocarditis-
related LGE should resolve 
first.  
Differences:  
While ACC/AHA scientific statements mention a possible minimum of 3 months of 
abstinence from sport, European consensus and position papers tend to focus more on 6 
months of abstinence. European recommendations included the necessity of absence of 
symptoms, LV ventricular dysfunction and arrhythmias upon clinical assessment, while 
ACC/AHA recommendations also consider biomarkers and the possibility of CMR.  
 
 
  
Ac
ce
pte
d m
an
us
cri
pt
36 
 
Figure legends 
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Central Illustration. Proposed diagnostic and treatment algorithm in the assessment of 
athletes who present with a clinical syndrome of current/recent infection and suspected 
myocarditis. 
BNP = Brain Natriuretic Peptide; CAD = Coronary Artery Disease; ECG = Electrocardiogram; 
LLC = Lake Louise Criteria; LVEF = Left Ventricular Ejection Fraction; RVEF = Right 
Ventricular Ejection Fraction; T2-w = T2-weighted; 
 
 
 
 
Figure 1. Examples of different myocarditis cases in athletes.  
Panel A (CMR scan 10 days after onset of symptoms) represents a case of a 39 years-old 
recreational athlete who presented with chest pain, increased troponin, ST elevation and 
depressed LVEF. LGE showed midwall and subepicardial hyperenhancement in the lateral wall 
(white arrows) with corresponding epicardial myocardial edema (hyperintensity signal) in the T2 
weighted images. Treadmill tests revealed ventricular couplet but no cardiac event was reported 
after a 1-year follow-up.s. Panel B (CMR scan 3 days after onset of symptoms) shows a soccer 
player presenting with syncope during exercise. Laboratory testing’s showed no troponin 
increase but T waves inversion were seen on ECG. The CMR showed no LV hypertrophy, 
butLV dilation, normal RV dimension and preserved LVEF.  There was no myocardial oedema 
seen on T2 weighted imaging and no LGE present. Acute myocarditis was therefore unlikely. 
Multiple serial follow-up exercise testing and ECG Holter were normal. Competitive physical 
activity was resumed with no further cardiac event during a 9-month follow-up. Panel C 
represents a 49 years old recreational athlete with acute chest pain. EKG showed ST elevation 
and Troponin I was elevated with 44792 ng/L. Invasive coronary angiogram could exclude a 
coronary artery disease. The CMR was performed 3 days after symptoms onset and LGE images 
showed epicardial enhancement on the lateral wall consistent with acute myocarditis. T2-
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weighted imaging showed a hyperintensity signal in the lateral wall and T2 mapping depicted 
increased T2 time in the same region (60 ms) compared to the inferior wall and the septum (36 
ms). These findings corresponded to intramyocardial edema. Native T1 mapping native showed 
increased T1 time in the lateral wall (1466 ms) compared to septum (1280 ms), anterior (1293 
ms) and inferior wall (1329 ms).  
 
LV = left ventricular; EF = ejection fraction; ESV = end-systolic volume; EDV = end-diastolic 
volume; RV = right ventricular; T2-w = T2-weighted  
 
 
 
 
Figure 2. Case of a 62-year-old competitive triathlete who experienced vertigo and syncope 
of 10 seconds on maximal exertion during cycling.  
Electrocardiogram and 24h Holter were normal. Ergometry was normal except ventricular 
triplets. Coronary arteries were normal on invasive coronary angiography. Echocardiography 
was normal except mild dilatation of all cardiac chambers. Severe upper respiratory tract 
infection was remembered two months ago. Laboratory testing including inflammation 
parameters and cardiac biomarkers were normal. CMR 1 months after the syncope showed large 
extent of epicardial late gadolinium enhancement (panel A and B, white arrows) anterior and 
inferior/inferolateral (midventricular) and small amount in the septum seen on the two-chamber, 
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three chamber and short-axis view. There was no corresponding myocardial edema visible in the 
T2-weighted imaging (panel C, short axis view shows signal intensity ratio of myocardium 
compared to skeletal muscle less than 2.0). The diagnosis of myocarditis was made (however, 
not “acute” at the time of the CMR scan).The athlete was recommended to abstain from 
strenuous exercise. After implantation of a Reveal recorder, the athlete continued (against the 
advice of the physician) with high intensity training and experienced a pre-syncope and a 
ventricular tachycardia of 333/min for 8 seconds (1 months after the CMR was done) recorded 
on the reveal device (panel D). The recommended beta-blocker was taken infrequently by the 
athlete and he denied any further electrophysiology study or intra-cardiac defibrillator 
implantation evaluation. He continued his high intensity trainings (again against the physician 
advice) and five months after first syncope the athlete died during a strenuous training of a 
sudden cardiac death. 
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